TD Asset Management Inc Has $1.73 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

TD Asset Management Inc grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 9.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,449 shares of the company’s stock after purchasing an additional 4,178 shares during the period. TD Asset Management Inc owned about 0.06% of Intellia Therapeutics worth $1,725,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp lifted its holdings in shares of Intellia Therapeutics by 31.1% during the second quarter. State Street Corp now owns 3,143,811 shares of the company’s stock worth $162,724,000 after buying an additional 746,284 shares in the last quarter. Eventide Asset Management LLC acquired a new position in Intellia Therapeutics in the third quarter valued at about $17,851,000. Goldman Sachs Group Inc. raised its stake in Intellia Therapeutics by 59.7% in the second quarter. Goldman Sachs Group Inc. now owns 848,183 shares of the company’s stock valued at $43,902,000 after purchasing an additional 317,167 shares in the last quarter. Polar Capital Holdings Plc acquired a new position in Intellia Therapeutics in the first quarter valued at about $18,713,000. Finally, BlackRock Inc. raised its stake in Intellia Therapeutics by 4.1% in the third quarter. BlackRock Inc. now owns 6,128,140 shares of the company’s stock valued at $342,930,000 after purchasing an additional 240,741 shares in the last quarter. 85.61% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $43.98 on Wednesday. The company has a market capitalization of $3.88 billion, a PE ratio of -8.16 and a beta of 1.86. The business has a fifty day moving average price of $38.28 and a two-hundred day moving average price of $41.02. Intellia Therapeutics, Inc. has a 1 year low of $32.44 and a 1 year high of $76.45.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last issued its earnings results on Thursday, May 4th. The company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.24. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 804.94%. The business had revenue of $12.60 million during the quarter, compared to the consensus estimate of $11.76 million. During the same quarter last year, the company earned ($1.96) EPS. The firm’s revenue was up 11.5% compared to the same quarter last year. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on NTLA shares. EF Hutton Acquisition Co. I dropped their price target on Intellia Therapeutics from $123.00 to $116.00 and set a “buy” rating for the company in a research note on Friday, February 24th. Sanford C. Bernstein assumed coverage on Intellia Therapeutics in a research note on Tuesday, March 21st. They set an “outperform” rating and a $54.00 target price for the company. StockNews.com assumed coverage on Intellia Therapeutics in a research note on Thursday, March 16th. They set a “sell” rating for the company. BMO Capital Markets boosted their target price on Intellia Therapeutics from $57.00 to $64.00 in a research note on Friday, May 5th. Finally, William Blair reissued an “outperform” rating on shares of Intellia Therapeutics in a research note on Wednesday, March 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $86.06.

Intellia Therapeutics Company Profile

(Get Rating)

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.